PARP1 and cancer: Numerous ongoing clinical trials are currently investigating the potential of combining immune checkpoint inhibitors (ICI) with various therapeutic approaches for cancer treatment, with the combination strategy involving PARP inhibitors (PARPi) attracting particular attention.